Gecacitinib to prevent graft-versus-host disease after stem cell transplant
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests whether a new medication called gecacitinib can prevent a common complication after a stem cell transplant for myelofibrosis. The complication, called graft-versus-host disease, happens when donor cells attack the patient's body. The drug is given before and after the transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older and have been diagnosed with myelofibrosis (either the primary type or the type that develops after other blood diseases like ET or PV).
- You must be planning to have a stem cell transplant using a matched sibling, matched unrelated, or half-matched (haploidentical) donor.
- You should be reasonably active—able to care for most of your own needs—and have good heart, lung, liver, and kidney function.
- You must be willing to avoid pregnancy or fathering a child during the study, using reliable contraception.
- You must be able to swallow pills and follow the study schedule.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether taking the study drug gecacitinib (a JAK inhibitor, which helps control blood cell counts and symptoms) before, during, and after a stem cell transplant improves outcomes for people with myelofibrosis. The goal is to see if it can make the transplant safer and more effective.
This trial tests a new drug, gecacitinib, for patients with moderate to severe chronic graft-versus-host disease (cGVHD) that has not improved after 2 to 5 prior treatments. It aims to see if the drug is safe and effective.
This trial tests a new pill called gecacitinib for people whose chronic graft-versus-host disease (a condition where donor cells attack their body after a stem cell transplant) has not gotten better with steroids. The drug aims to control the disease and help you feel better.
This study tests a new pill (gecacitinib) combined with steroids as the first treatment for moderate to severe acute graft-versus-host disease after a stem cell transplant. The goal is to see if this combination works better than steroids alone.
This study tests an experimental medicine called gecacitinib for people who have graft-versus-host disease (GVHD) after a stem cell transplant and whose GVHD did not improve with standard second-line treatment (ruxolitinib). The goal is to see if this new treatment can help control GVHD symptoms.
This trial tests a combination of medications given before and after a stem cell transplant from a family member to prevent graft-versus-host disease (GVHD)—a condition where the new cells attack your body. The study includes a newer drug called ivarmacitinib that may help reduce this serious side effect.
Hear when a new aGVHD Prophylaxis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.